https://scholars.lib.ntu.edu.tw/handle/123456789/638440
Title: | Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial | Authors: | Brose, Marcia S Robinson, Bruce G Sherman, Steven I Jarzab, Barbara CHIA-CHI LIN Vaisman, Fernanda Hoff, Ana O Hitre, Erika Bowles, Daniel W Sen, Suvajit Oliver, Jennifer W Banerjee, Kamalika Keam, Bhumsuk Capdevila, Jaume |
Keywords: | COSMIC-311; cabozantinib; differentiated thyroid cancer; phase 3; placebo; tyrosine kinase inhibitor | Issue Date: | 15-Dec-2022 | Journal Volume: | 128 | Journal Issue: | 24 | Source: | Cancer | Abstract: | At an interim analysis (median follow-up, 6.2 months; n = 187), the phase 3 COSMIC-311 trial met the primary end point of progression-free survival (PFS): cabozantinib improved PFS versus a placebo (median, not reached vs. 1.9 months; p < .0001) in patients with previously treated radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). The results from an exploratory analysis using an extended datacut are presented. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638440 | ISSN: | 0008543X | DOI: | 10.1002/cncr.34493 |
Appears in Collections: | 臨床醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.